Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam in High Risk ERCP
NCT06258356Not yet recruiting
- Sponsor
- National Taiwan University Hospital
- Start
- Feb 2024
- Primary completion
- Dec 2028
- Modality
- Small Molecules
01
Overview
Randomised trial comparing Remimazolam with Placebo (2 arms). Primary endpoint: Duration and severity of hypotension checklist at 1 day. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
remimazolam
Beyond the preview
Go deeper on NCT06258356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06258356.